Search

Your search keyword '"Cave H."' showing total 9 results
Start Over Author "Cave H." Publisher springer nature
9 results on '"Cave H."'

1. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group

Author

Hirabayashi, S, Butler, E, Ohki, K, Kiyokawa, N, Bergmann, A, Moricke, A, Boer, J, Cave, H, Cazzaniga, G, Yeoh, A, Sanada, M, Imamura, T, Inaba, H, Mullighan, C, Loh, M, Noren-Nystrom, U, Pastorczak, A, Shih, L, Zaliova, M, Pui, C, Haas, O, Harrison, C, Moorman, A, Manabe, A, Hirabayashi S., Butler E. R., Ohki K., Kiyokawa N., Bergmann A. K., Moricke A., Boer J. M., Cave H., Cazzaniga G., Yeoh A. E. J., Sanada M., Imamura T., Inaba H., Mullighan C., Loh M. L., Noren-Nystrom U., Pastorczak A., Shih L. -Y., Zaliova M., Pui C. -H., Haas O. A., Harrison C. J., Moorman A. V., Manabe A., Hirabayashi, S, Butler, E, Ohki, K, Kiyokawa, N, Bergmann, A, Moricke, A, Boer, J, Cave, H, Cazzaniga, G, Yeoh, A, Sanada, M, Imamura, T, Inaba, H, Mullighan, C, Loh, M, Noren-Nystrom, U, Pastorczak, A, Shih, L, Zaliova, M, Pui, C, Haas, O, Harrison, C, Moorman, A, Manabe, A, Hirabayashi S., Butler E. R., Ohki K., Kiyokawa N., Bergmann A. K., Moricke A., Boer J. M., Cave H., Cazzaniga G., Yeoh A. E. J., Sanada M., Imamura T., Inaba H., Mullighan C., Loh M. L., Noren-Nystrom U., Pastorczak A., Shih L. -Y., Zaliova M., Pui C. -H., Haas O. A., Harrison C. J., Moorman A. V., and Manabe A.

Published
2021

2. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

Author

Boer, J, Valsecchi, M, Hormann, F, Antic, Z, Zaliova, M, Schwab, C, Cazzaniga, G, Arfeuille, C, Cave, H, Attarbaschi, A, Strehl, S, Escherich, G, Imamura, T, Ohki, K, Gruber, T, Sutton, R, Pastorczak, A, Lammens, T, Lambert, F, Li, C, Carrillo de Santa Pau, E, Hoffmann, S, Moricke, A, Harrison, C, Den Boer, M, De Lorenzo, P, Stam, R, Bergmann, A, Pieters, R, Boer J. M., Valsecchi M. G., Hormann F. M., Antic Z., Zaliova M., Schwab C., Cazzaniga G., Arfeuille C., Cave H., Attarbaschi A., Strehl S., Escherich G., Imamura T., Ohki K., Gruber T. A., Sutton R., Pastorczak A., Lammens T., Lambert F., Li C. K., Carrillo de Santa Pau E., Hoffmann S., Moricke A., Harrison C. J., Den Boer M. L., De Lorenzo P., Stam R. W., Bergmann A. K., Pieters R., Boer, J, Valsecchi, M, Hormann, F, Antic, Z, Zaliova, M, Schwab, C, Cazzaniga, G, Arfeuille, C, Cave, H, Attarbaschi, A, Strehl, S, Escherich, G, Imamura, T, Ohki, K, Gruber, T, Sutton, R, Pastorczak, A, Lammens, T, Lambert, F, Li, C, Carrillo de Santa Pau, E, Hoffmann, S, Moricke, A, Harrison, C, Den Boer, M, De Lorenzo, P, Stam, R, Bergmann, A, Pieters, R, Boer J. M., Valsecchi M. G., Hormann F. M., Antic Z., Zaliova M., Schwab C., Cazzaniga G., Arfeuille C., Cave H., Attarbaschi A., Strehl S., Escherich G., Imamura T., Ohki K., Gruber T. A., Sutton R., Pastorczak A., Lammens T., Lambert F., Li C. K., Carrillo de Santa Pau E., Hoffmann S., Moricke A., Harrison C. J., Den Boer M. L., De Lorenzo P., Stam R. W., Bergmann A. K., and Pieters R.

Published
2021

3. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (Leukemia, (2019), 33, 8, (1910-1922), 10.1038/s41375-019-0413-0)

Author

Pfeifer H., Pfeifer, H, Cazzaniga, G, van der Velden, V, Cayuela, J, Schafer, B, Spinelli, O, Akiki, S, Avigad, S, Bendit, I, Borg, K, Cave, H, Elia, L, Reshmi, S, Gerrard, G, Hayette, S, Hermanson, M, Juh, A, Jurcek, T, Chillon, M, Homburg, C, Martinelli, G, Kairisto, V, Lange, T, Lion, T, Mueller, M, Pane, F, Rai, L, Damm-Welk, C, Sacha, T, Schnittger, S, Touloumenidou, T, Valerhaugen, H, Vandenberghe, P, Zuna, J, Serve, H, Herrmann, E, Markovic, S, van Dongen, J, Ottmann, O, Pfeifer H., Cazzaniga G., van der Velden V. H. J., Cayuela J. M., Schafer B., Spinelli O., Akiki S., Avigad S., Bendit I., Borg K., Cave H., Elia L., Reshmi S. C., Gerrard G., Hayette S., Hermanson M., Juh A., Jurcek T., Chillon M. C., Homburg C., Martinelli G., Kairisto V., Lange T., Lion T., Mueller M. C., Pane F., Rai L., Damm-Welk C., Sacha T., Schnittger S., Touloumenidou T., Valerhaugen H., Vandenberghe P., Zuna J., Serve H., Herrmann E., Markovic S., van Dongen J. J. M., Ottmann O. G., Pfeifer H., Pfeifer, H, Cazzaniga, G, van der Velden, V, Cayuela, J, Schafer, B, Spinelli, O, Akiki, S, Avigad, S, Bendit, I, Borg, K, Cave, H, Elia, L, Reshmi, S, Gerrard, G, Hayette, S, Hermanson, M, Juh, A, Jurcek, T, Chillon, M, Homburg, C, Martinelli, G, Kairisto, V, Lange, T, Lion, T, Mueller, M, Pane, F, Rai, L, Damm-Welk, C, Sacha, T, Schnittger, S, Touloumenidou, T, Valerhaugen, H, Vandenberghe, P, Zuna, J, Serve, H, Herrmann, E, Markovic, S, van Dongen, J, Ottmann, O, Pfeifer H., Cazzaniga G., van der Velden V. H. J., Cayuela J. M., Schafer B., Spinelli O., Akiki S., Avigad S., Bendit I., Borg K., Cave H., Elia L., Reshmi S. C., Gerrard G., Hayette S., Hermanson M., Juh A., Jurcek T., Chillon M. C., Homburg C., Martinelli G., Kairisto V., Lange T., Lion T., Mueller M. C., Pane F., Rai L., Damm-Welk C., Sacha T., Schnittger S., Touloumenidou T., Valerhaugen H., Vandenberghe P., Zuna J., Serve H., Herrmann E., Markovic S., van Dongen J. J. M., and Ottmann O. G.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

4. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

Author

van der Velden, V. H. J., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer-Grumayer, E. R., Flohr, T., Sutton, R., Cave, H., Madsen, H. O., Cayuela, J. M., Trka, J., Eckert, C., Foroni, L., zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C. E., and van Dongen, J. J. M.

Subjects
LYMPHOBLASTIC leukemia treatment, DIAGNOSTIC use of polymerase chain reaction, IMMUNOGLOBULINS, T-cell receptor genes, QUALITY control, GUIDELINES, DRUGS
Abstract

Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs.Leukemia (2007) 21, 604–611. doi:10.1038/sj.leu.2404586; published online 8 February 2007 [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

5. Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma.

Author

Soufir, N., Lacapere, J.J., Bertrand, G., Matichard, E., Meziani, R., Mirebeau, D., Descamps, V., Gérard, B., Archimbaud, A., Ollivaud, L., Bouscarat, F., Baccard, M., Lanternier, G., Saïag, P., Lebbé, C., Basset-Seguin, N., Crickx, B., Cave, H., and Grandchamp, B.

Subjects
MELANOMA, GENETIC mutation, TUMORS, CANCER, ONCOLOGY
Abstract

Germline anomalies of the INK4a-ARF and Cdk4 genes were sought in a series of 89 patients suspected of having a genetic predisposition to melanoma. Patients were selected based on the following criteria: (a) familial melanoma (23 cases), (b) multiple primary melanoma (MPM; 18 cases), (c) melanoma and additional unrelated cancers (13 cases), (d) age at diagnosis less than 25 years (21 cases), and (e) nonphoto-induced melanoma (NPIM; 14 cases). Mutations of INK4a-ARF and Cdk4 were characterised by automated sequencing, and germline deletions of INK4a-ARF were also examined by real-time quantitative PCR. Seven germline changes of INK4a-ARF, five of which were novel, were found in seven patients (8%). Four were very likely to be pathogenic mutations and were found in three high-risk melanoma families and in a patient who had a pancreatic carcinoma in addition to melanoma. Three variants of uncertain significance were detected in one MPM patient, one patient <25 years, and one NPIM patient. No germline deletion of INK4a-ARF was found in 71 patients, and no Cdk4 mutation was observed in the 89 patients. This study confirms that INK4a-ARF mutations are infrequent outside stringent familial criteria, and that germline INK4a-ARF deletions are rarely involved in genetic predisposition to melanoma.British Journal of Cancer (2004) 90, 503-509. doi:10.1038/sj.bjc.6601503 www.bjcancer.com [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

6. CORRESPONDENCE.

Author

Guidal, C., Vilmer, E., Grandchamp, B., Cave, H., Taub, J.W., Matherly, L.H., Ravindranath, Y., Kaspers, G.-J.L., Rots, M.G., and van Zantwijk, C.H.

Subjects
LYMPHOBLASTIC leukemia, LEUKEMIA
Abstract

Presents several views and counter-views on acute lymphoblastic leukemia. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on the study of leukemia.

Published
2002

7. Expansion of polyclonal B-cell precursors in bone marrow from children treated for acute lymphoblastic leukemia.

Author

Duval, M., Fenneteau, O., Cave, H., Gobillot, C., Rohrlich, P., Guidal, C., Lescoeur, B., Legac, S., Schlegel, N., Sterkers, G., and Vilmer, E.

Abstract

In a series of 12 patients (mean age: 3 years at diagnosis) receiving chemotherapy for acute lymphoblastic leukemia, bone marrow examinations performed during hematopoietic recovery following treatment-induced agranulocytosis or completion of maintenance treatment showed at least 15% of non malignant immature cells which were sometimes hardly distinguishable from leukemic cells. No comparable data was observed in patients treated with G-CSF. The cytological features of these cells as well as their immunophenotyping were defined. Results showed that the majority of cells expressed HLA-DR, CD19, CD10 and cytoplasmic IgM but not the CD34 markers. This predominant and homogeneous pre-B cell population which likely represents the expansion of a minor population detectable in normal bone marrow is phenotypically indistinguishable from leukemic cells. The pattern of IgH gene rearrangements studied by PCR amplification of the CDRIII region showed that these cells were polyclonal. Except in one patient, minimal residual disease was not detected using probes specific for IgH or TCR gene rearrangement of the malignant clone. In children during the hematopoietic recovery after chemotherapy, immature marrow cells in great numbers, even with an highly homogenous immunophenotype identical to the malignant clone’s, are not sufficient for the diagnosis of relapse. [ABSTRACT FROM AUTHOR]

Published
1997
Full Text
View/download PDF

9. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group

Author

Christine J. Harrison, Anja Möricke, Ching-Hon Pui, Marketa Zaliova, Hiroto Inaba, Ulrika Norén-Nyström, Kentaro Ohki, Toshihiko Imamura, Judith M. Boer, Atsushi Manabe, Shinsuke Hirabayashi, Allen Eng Juh Yeoh, Oskar A. Haas, Masashi Sanada, Nobutaka Kiyokawa, Ellie Butler, Anke K. Bergmann, Giovanni Cazzaniga, Lee Yung Shih, Hélène Cavé, Anthony V. Moorman, Charles G. Mullighan, Agata Pastorczak, Mignon L. Loh, Hirabayashi, S, Butler, E, Ohki, K, Kiyokawa, N, Bergmann, A, Moricke, A, Boer, J, Cave, H, Cazzaniga, G, Yeoh, A, Sanada, M, Imamura, T, Inaba, H, Mullighan, C, Loh, M, Noren-Nystrom, U, Pastorczak, A, Shih, L, Zaliova, M, Pui, C, Haas, O, Harrison, C, Moorman, A, and Manabe, A

Subjects
Adult, Male, Cancer Research, Pediatrics, medicine.medical_specialty, Letter, Adolescent, MEDLINE, Acute lymphoblastic leukemia, Young Adult, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Biomarkers, Tumor, Retrospective analysis, Humans, Medicine, Child, Cancer genetics, Childhood all, Retrospective Studies, Gene Rearrangement, Cancer och onkologi, Acute lymphocytic leukaemia, business.industry, Infant, Hematology, Prognosis, Survival Rate, Oncology, Child, Preschool, Cancer and Oncology, Trans-Activators, Female, business, Follow-Up Studies
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results